Tetraphase Pharma’s Antibiotic Wins FDA Approval for Gut Infections

A Tetraphase Pharmaceuticals antibiotic has earned FDA approval, adding a new treatment to the effort to address drug-resistant infections.

The FDA decision for the Tetraphase (NASDAQ: TTPH) drug, eravacycline (Xerava), covers complicated intra-abdominal infections (cIAI) in adults.